Țară: Canada
Limbă: engleză
Sursă: Health Canada
CLODRONATE DISODIUM
SUMITOMO PHARMA CANADA, INC.
M05BA02
CLODRONIC ACID
400MG
CAPSULE
CLODRONATE DISODIUM 400MG
ORAL
15G/50G
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0122982001; AHFS:
APPROVED
2004-12-01
_ _ _ _ _Page 1 of 28_ PRODUCT MONOGRAPH Pr CLASTEON ® clodronate disodium capsules, 400 mg Bone Metabolism Regulator Sumitomo Pharma Canada, Inc. 7025 Langer Drive, Suite 301 Mississauga, Ontario Canada L5N 0E8 Licensed by ABIOGEN PHARMA S.p.A Italy Control # : 279085 Date of Preparation: OCT 17, 2023 _ _ _ _ _Page 2 of 28_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................11 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................13 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................13 PART II: SCIENTIFIC INFORMATION ...............................................................................14 PHARMACEUTICAL INFORMATION ..........................................................................14 CLINICAL TRIALS ..........................................................................................................15 DETAILED PHARMACOLOGY ............................ Citiți documentul complet